Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | GPR4 | P46093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281500 | 0.89 | HRH3 (0.49) | GBA1HRH3HRH4KCNH2SLC6A4 | |
| SCHEMBL21358938 | 0.89 | HRH3 (0.49) | GBA1HRH3HRH4KCNH2SLC6A4 | |
| SCHEMBL21603172 | 0.89 | HRH3 (0.49) | GBA1HRH3HRH4KCNH2SLC6A4 | |
| SCHEMBL3967185 | 0.81 | GBA1 (0.55) | GBA1HRH3HRH4KCNH2SLC6A4 | |
| SCHEMBL12696626 | 0.80 | GBA1 (0.50) | GBA1HRH3HRH4KCNH2SLC6A4 | |
| SCHEMBL21359121 | 0.80 | EED (0.52) | HRH3HRH4KCNH2 | |
| SCHEMBL20281478 | 0.80 | EED (0.52) | HRH3HRH4KCNH2 | |
| SCHEMBL20281932 | 0.79 | HRH4 (0.43) | GBA1HRH3HRH4KCNH2SLC6A4 | |
| SCHEMBL20281523 | 0.78 | HRH4 (0.42) | GBA1HRH3HRH4KCNH2SLC6A4 | |
| SCHEMBL21603160 | 0.77 | EED (0.44) | GBA1HRH3HRH4SLC6A4TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GBA1 18/4885HRH3 3480/4885HRH4 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.